RESUMEN
INTRODUCTION: Performance and image-enhancing drugs (PIEDs), also known as "lifestyle drugs," are increasingly sold on the Internet to enhance cognitive as well as sexual, muscular, attentive, and other natural capacities. Our analysis focuses on the misuse of the cognitive enhancer piracetam. METHODS: A literature review was carried out in PsychInfo and Pubmed database. Considering the absence of peer-reviewed data, review of additional sources of unstructured information from the Internet was carried out between February 2012 and July 2013. Additional searches were conducted using the Global Public Health Intelligence Network (GPHIN), a secure Internet-based early warning system developed by Health Canada and the World Health Organization (WHO), which monitors media reports in six languages, Arabic, Chinese, English, French, Russian, and Spanish. RESULTS: Piracetam is sold via illicit online pharmacies with no need of prescription at low prices. Buyers, mainly healthy individuals, purchase the product to enhance study- and work-related performances as well as for recreational purposes. Its nonmedical use is often associated with the occurrence of side effects such as hallucinations, psychomotor agitation, dysphoria, tiredness, dizziness, memory loss, headache, and severe diarrhoea; moreover, several users declared to have neither felt any cognitive improvement nor psychedelic effects. CONCLUSIONS: This is a new and fast-growing trend of abuse that needs to be extensively monitored and studied also by using near real-time and unstructured sources of information such as Internet news and online reports in order to acquire rapid knowledge and understanding. Products sold online might be counterfeits and this enhances related health risks.
Asunto(s)
Drogas Ilícitas/provisión & distribución , Nootrópicos/provisión & distribución , Sustancias para Mejorar el Rendimiento/provisión & distribución , Piracetam/provisión & distribución , Comercio , Humanos , Drogas Ilícitas/efectos adversos , Internet , Nootrópicos/efectos adversos , Nootrópicos/uso terapéutico , Sustancias para Mejorar el Rendimiento/efectos adversos , Sustancias para Mejorar el Rendimiento/uso terapéutico , Disponibilidad de Medicamentos Vía Internet , Piracetam/efectos adversos , Piracetam/uso terapéutico , Trastornos Relacionados con SustanciasRESUMEN
The 2015 Varsity Medical Ethics debate convened upon the motion: "This house believes nootropic drugs should be available under prescription". This annual debate between students from the Universities of Oxford and Cambridge, now in its seventh year, provided the starting point for arguments on the subject. The present article brings together and extends many of the arguments put forward during the debate. We explore the current usage of nootropic drugs, their safety and whether it would be beneficial to individuals and society as a whole for them to be available under prescription. The Varsity Medical Debate was first held in 2008 with the aim of allowing students to engage in discussion about ethics and policy within healthcare. The event is held annually and it is hoped that this will allow future leaders to voice a perspective on the arguments behind topics that will feature heavily in future healthcare and science policy. This year the Oxford University Medical Society at the Oxford Union hosted the debate.
Asunto(s)
Disentimientos y Disputas , Ética Médica , Nootrópicos/provisión & distribución , Medicamentos bajo Prescripción , Medicina Estatal , Humanos , Reino UnidoAsunto(s)
Enfermedad de Alzheimer/enfermería , Hogares para Ancianos/normas , Nootrópicos/uso terapéutico , Casas de Salud/estadística & datos numéricos , Anciano , Enfermedad de Alzheimer/tratamiento farmacológico , Antidepresivos/efectos adversos , Antidepresivos/uso terapéutico , Utilización de Medicamentos/estadística & datos numéricos , Alemania , Encuestas Epidemiológicas , Humanos , Evaluación de Necesidades , Nootrópicos/efectos adversos , Nootrópicos/provisión & distribución , Psicotrópicos/efectos adversos , Psicotrópicos/uso terapéutico , Resultado del TratamientoRESUMEN
BACKGROUND: Alzheimer's drugs are believed to have limited availability and to be unaffordable in low- and middle-income countries compared to high-income countries. The price, availability and affordability of Alzheimer's drugs have not been reported before. METHODS: During 2007 an international survey was conducted in 21 countries in six continents (Argentina, Australia, Brazil, the Dominican Republic, France, India, Japan, Macedonia, Mexico, New Zealand, Nigeria, the Philippines, Portugal, Serbia, South Korea, Switzerland, Taiwan, Thailand, Uganda, the U.K. and the U.S.A.). Prices of Alzheimer's drugs were compared using the affordability index (the total number of units purchasable with one's daily income) derived from purchasing power parity (PPP) converted prices as well as raw prices. RESULTS: Donepezil is available in all 21 countries, whereas the newer drugs are less available. A 5 mg tablet of branded originator donepezil costs just US$0.26 in India and US$0.31 in Mexico, whereas it costs US$6.64 in the U.S.A. Pricing conditions of rivastigmine, galantamine and memantine appear to be similar to that of donepezil. The cheapest branded originators are from India and Mexico. However, in terms of PPP, Alzheimer's drugs in other low- and middle-income countries are much more expensive than in high-income countries. Most people in low- and middle-income countries cannot afford Alzheimer's drugs. CONCLUSIONS: Alzheimer's drugs, albeit available, are often unaffordable for those who need them most. It is hoped that equitable differential pricing will be applied to Alzheimer's drugs.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/economía , Comparación Transcultural , Costos de los Medicamentos/estadística & datos numéricos , Nootrópicos/economía , Nootrópicos/uso terapéutico , Anciano , Países en Desarrollo , Donepezilo , Economía , Galantamina/economía , Galantamina/provisión & distribución , Galantamina/uso terapéutico , Humanos , Renta , Indanos/economía , Indanos/provisión & distribución , Indanos/uso terapéutico , India , Memantina/economía , Memantina/provisión & distribución , Memantina/uso terapéutico , México , Nootrópicos/provisión & distribución , Fenilcarbamatos/economía , Fenilcarbamatos/provisión & distribución , Fenilcarbamatos/uso terapéutico , Piperidinas/economía , Piperidinas/provisión & distribución , Piperidinas/uso terapéutico , Rivastigmina , Estados UnidosRESUMEN
AIDS: The PWA Health Group will begin carrying L-acetyl-carnitine. Studies show that d4T and ddI may cause neuropathy by lowering L-acetyl-carnitine levels; however, there have been no controlled studies showing that L-acetyl-carnitine therapy is effective. A study involving the elderly showed that L-acetyl-carnitine offered significant improvement in cognitive function, with no serious side effects. L-acetyl-carnitine and L-carnitine are not the same. The strength of L-carnitine varies greatly in the pills available in health food stores and the prescription drug L-Carnitor is recommended.^ieng